Related Experiment Video
Updated: Aug 13, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Neoadjuvant befotertinib plus vorolanib in resectable stage II-IIIB EGFR-mutant NSCLC: a study protocol for the
Leilei Wu1, Lei Cai1, Da Chen1
1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background:
Neoadjuvant targeted therapy is a promising strategy for resectable non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, but pathological regression remains suboptimal with EGFR-tyrosine kinase inhibitor (TKI) monotherapy. Befotertinib is a third-generation EGFR-TKI, whereas vorolanib is a multi-target antiangiogenic TKI. Combined EGFR and vascular endothelial growth factor receptor (VEGFR) pathway inhibition may enhance tumor regression while preserving surgical feasibility.
Methods:
This is a prospective, open-label, single-arm phase I/II study enrolling NSCLC patients with clinically resectable stage II-IIIB harboring sensitizing EGFR exon 19 deletion and/or exon 21 L858R mutations. Phase I uses a 3+3 dose-escalation design to determine the maximum tolerated dose and recommended phase II dose of neoadjuvant befotertinib plus vorolanib. Phase II adopts a two-stage design and evaluates major pathological response after two 21-day neoadjuvant cycles. Patients undergo radiographic assessment after neoadjuvant therapy, followed by radical surgery 4-6 weeks after the last treatment dose. Secondary endpoints include pathological complete response, R0 resection rate, objective response rate, disease control rate, safety, disease-free survival, and overall survival.
Discussion:
This trial will prospectively explore the feasibility, safety, and preliminary activity of combined third-generation EGFR inhibition and antiangiogenic therapy in resectable stage II-IIIB EGFR-mutant NSCLC. The study may help define whether intensification of neoadjuvant targeted therapy can improve pathological regression in this molecularly selected population.
Trial Registration:
Chinese Clinical Trial Registry (ChiCTR2500103324).
Insights
This study investigates combining befotertinib (EGFR inhibitor) and vorolanib (antiangiogenic) for resectable EGFR-mutant non-small cell lung cancer (NSCLC). The goal is to improve pathological regression with neoadjuvant targeted therapy before surgery.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Neoadjuvant targeted therapy shows promise for resectable EGFR-mutant non-small cell lung cancer (NSCLC).
- Current EGFR-tyrosine kinase inhibitor (TKI) monotherapy offers suboptimal pathological regression.
- Befotertinib (3rd-gen EGFR-TKI) combined with vorolanib (multi-target antiangiogenic TKI) may enhance tumor regression by inhibiting both EGFR and VEGFR pathways.
Purpose of the Study:
- To explore the feasibility, safety, and preliminary activity of combined neoadjuvant befotertinib and vorolanib.
- To determine if intensified neoadjuvant targeted therapy can improve pathological regression in EGFR-mutant NSCLC.
- To evaluate the combination's potential in resectable stage II-IIIB EGFR-mutant NSCLC.
Main Methods:
- Prospective, open-label, single-arm Phase I/II study.
- Enrollment of NSCLC patients with resectable stage II-IIIB and EGFR exon 19 deletion and/or exon 21 L858R mutations.
- Phase I: 3+3 dose escalation for befotertinib plus vorolanib. Phase II: Two-stage design evaluating major pathological response after two neoadjuvant cycles.
Main Results:
- N/A - Study is ongoing, results not yet available.
Conclusions:
- N/A - Study is ongoing, conclusions not yet available.
